Biology Reference
In-Depth Information
MALDI mass spectrometry.
J Am Soc Mass Spectrom
2002;
43. Kim HK, Reyzer ML, Choi IJ, et al. Gastric cancer-
speci
(11):1292
e
7.
30. Drake RR, Cazares LH, Jones EE, Fuller TW,
Semmes OJ, Laronga C. Challenges to developing
proteomic-based breast cancer diagnostics.
OMICS
2011;
ed using endoscopic
biopsy samples via MALDI mass spectrometry.
J Pro-
teome Res
2010;
c protein pro
le identi
13
(8):4123
e
30.
9
44. M
Koma AE, Seeley EH, Washington MK, et al. Pro-
teomic pro
'
(5):251
e
9.
31. SchwambornK, KriegRC, ReskaM, JakseG, Knuechel R,
Wellmann A.
ling of mucosal and submucosal colonic
tissues yields protein signatures that differentiate the
in
15
Identifying prostate
carcinoma by
ammatory colitides.
In
amm Bowel Dis
2011;
(4):
17
(2):155
e
9.
32. Cazares LH, Troyer D, Mendrinos S, et al. Imaging mass
spectrometry of a speci
MALDI-Imaging.
Int J Mol Med
2007;
875
e
83.
45. Corbin BD, Seeley EH, Raab A, et al. Metal chelation
and inhibition of bacterial growth in tissue abscesses.
Science
2008;
20
c fragment of mitogen-activated
protein kinase/extracellular signal-regulated kinase
kinase kinase 2 discriminates cancer from uninvolved
prostate tissue.
Clin Cancer Res
2009;
(5865):962
e
5.
46. Oswald-Richter KA, Beachboard DC, Seeley EH, et al.
Dual analysis for mycobacteria and propionibacteria in
sarcoidosis BAL.
J Clin Immunol
2012.
47. Oezdemir RF, Gaisa NT, Lindemann-Docter K, et al.
Proteomic tissue pro
319
(17):5541
e
51.
33. Oppenheimer SR, Mi D, Sanders ME, Caprioli RM.
Molecular analysis of tumor margins by MALDI mass
spectrometry in renal carcinoma.
J Proteome Res
2010;
9
15
ling for the improvement of
grading of noninvasive papillary urothelial neoplasia.
Clin Biochem
2012;
(5):2182
e
90.
34. Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM.
Protein signatures for survival and recurrence in
metastatic melanoma.
J Proteomics
2011;
(1
e
2):7
e
11.
48. Lemaire R, Desmons A, Tabet JC, Day R, Salzet M,
Fournier I. Direct analysis and MALDI imaging of
formalin-
45
(7):1002
e
14.
35. Chaurand P, DaGue BB, Pearsall RS, Threadgill DW,
Caprioli RM. Pro
74
xed, paraf
n-embedded tissue
sections.
ling proteins from azoxymethane-
induced colon tumors at the molecular level by
matrix-assisted laser desorption/ionization mass spec-
trometry.
Proteomics
2001;
(4):1295
e
305.
49. Casadonte R, Caprioli RM. Proteomic analysis of
formalin-
J Proteome Res
2007;
6
n-embedded tissue by MALDI
imaging mass spectrometry.
Nat Protoc
2011;
xed paraf
(10):1320
e
6.
36. Rahman SM, Gonzalez AL, Li M, et al. Lung cancer
diagnosis from proteomic analysis of preinvasive
lesions.
Cancer Res
2011;
(11):
1
6
1695
e
709.
50. Lazova R, Seeley EH, Keenan M, Gueorguieva R,
Caprioli RM. Imaging mass spectrometry
e
a new and
promising method to differentiate Spitz nevi from
Spitzoid malignant melanomas.
Am J Dermatopathol
2012;
(8):3009
e
17.
37. Rahman SM, Shyr Y, Yildiz PB, et al. Proteomic
patterns of preinvasive bronchial lesions.
Am J Respir
Crit Care Med
2005;
71
(12):1556
e
62.
38. Taguchi F, Solomon B, Gregorc V, et al. Mass spec-
trometry to classify non-small-cell lung cancer patients
for clinical outcome after treatment with epidermal
growth factor receptor tyrosine kinase inhibitors:
a multicohort cross-institutional study.
J Natl Cancer
Inst
2007;
(1):82
e
90.
51. Groseclose MR, Massion PP, Chaurand P, Caprioli RM.
High-throughput proteomic analysis of formalin-
172
34
xed
paraf
n-embedded tissue microarrays using MALDI
imaging mass
spectrometry.
Proteomics
2008;
(18):
8
3715
e
24.
52. Djidja MC, Claude E, Snel MF, et al. Novel molecular
tumour classi
(11):838
e
46.
39. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns
of tumour subsets in non-small-cell lung cancer.
Lancet
2003;
99
cation using MALDI-mass spectrometry
imaging of tissue micro-array.
Anal Bioanal Chem
2010;
397
(9382):433
e
9.
40. Yanagisawa K, Xu BJ, Carbone DP, Caprioli RM.
Molecular
(2):587
e
601.
53. Morita Y, Ikegami K, Goto-Inoue N, et al. Imaging mass
spectrometry of gastric carcinoma in formalin-
362
fingerprinting in human lung cancer.
Clin
Lung Cancer
2003;
xed
(2):113
e
8.
41. Gustafsson JO, Oehler MK, Ruszkiewicz A, McColl SR,
Hoffmann P. MALDI imaging mass spectrometry
(MALDI-IMS)-application of spatial proteomics for
ovarian cancer classi
5
paraf
n-embedded tissue microarray.
Cancer Sci
2010;
(1):267
e
73.
54. Schwamborn K, Wild P, Caprioli RM.
Uncovering
the Proteome of Late State Prostate Cancer by Imaging
Mass Spectrometry
. Salt Lake City, UT: 58th
ASMS Conference on Mass Spectrometry and Allied
Topics; 2010.
55. Hanrieder J, Ljungdahl A, Andersson M. MALDI
imaging mass spectrometry of neuropeptides in Par-
kinson
101
cation and diagnosis.
Int J Mol Sci
(1):773
e
94.
42. Balluff B, Rauser S, Meding S, et al. MALDI imaging
identi
2011;
12
es prognostic seven-protein signature of novel
tissue markers in intestinal-type gastric cancer.
Am J
Pathol
2011;
(6):2720
e
9.
'
s disease.
J Vis Exp
2012;
:3445.
179
60
Search WWH ::
Custom Search